Cyproterone acetate in the treatment of oestrogen hypersensitivity vulvovaginitis

Yvonne Nguyen; Jennifer Bradford; Gayle Fischer

doi:10.1111/ajd.12657

Cyproterone acetate in the treatment of oestrogen hypersensitivity vulvovaginitis

Australas J Dermatol. 2018 Feb;59(1):52-54. doi: 10.1111/ajd.12657. Epub 2017 Jul 18.

Authors

Yvonne Nguyen^{1

2}, Jennifer Bradford³, Gayle Fischer^{1

2

4}

Affiliations

¹ Department of Dermatology, Kolling Institute, Northern Sydney Local Health District, Sydney, New South Wales, Australia.
² Department of Dermatology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
³ University of Western Sydney, Sydney, New South Wales, Australia.
⁴ Sydney Medical School Northern, University of Sydney, Sydney, New South Wales, Australia.

PMID: 28718897
DOI: 10.1111/ajd.12657

Abstract

Oestrogen hypersensitivity vulvovaginitis is a rare chronic cyclical vulvovaginitis responsive to oestrogen suppression or antagonism. We present a case series of 16 patients with refractory cyclical vulvovaginitis, all of whom responded to oestrogen suppression with cyproterone acetate.

Keywords: EH; cyproterone acetate; estrogen hypersensitivity; oestrogen hypersensitivity; vulvitis.

MeSH terms

Adult
Chronic Disease
Cyproterone Acetate / therapeutic use*
Estrogen Antagonists / therapeutic use*
Estrogens / immunology*
Female
Humans
Hypersensitivity / complications*
Middle Aged
Vulvovaginitis / drug therapy*
Vulvovaginitis / immunology*
Young Adult

Substances

Estrogen Antagonists
Estrogens
Cyproterone Acetate